Roche announced it would stop development of emugrobart after a key study failed to show consistent muscle growth and motor function benefits; separately, Genentech halted a muscle‑preserving antibody after it failed to boost muscle in rare genetic disease trials. Both decisions prompt scrutiny of similar mechanisms being tested in obesity indications. Developers and investors will reassess risk for related trials that seek to preserve or boost muscle mass as part of metabolic or obesity strategies, and sponsors may need additional proof of functional benefit before advancing into larger, costlier obesity programs.